A New Venture Blooms From Controversial Roots

The partner of a once-celebrated Silicon Valley figure has secured significant funding for a new biotech venture. This startup, Haemanthus, aims to revolutionize medical testing using artificial intelligence. The name Haemanthus is inspired by the Greek word for "blood flower, " hinting at its focus on blood-related technologies. The individual behind this new endeavor is Billy Evans, who is backed by the notorious Elizabeth Holmes. Holmes, known for her role in the disgraced blood-testing company Theranos, is currently serving an 11-year prison sentence for deceiving investors. Despite her legal troubles, Holmes has been quietly advising Evans on his new venture from behind bars. The specifics of her involvement remain unclear, but her influence is evident. Haemanthus is in its early stages, with a team of about a dozen people. Many of these team members have a background in autonomous vehicle technology, bringing a unique perspective to the biotech field. The startup has primarily raised funds from friends, family, and supporters, indicating a strong personal network.

The technology at the heart of Haemanthus is Raman spectroscopy, a method that uses light to analyze biological materials. This technique has shown promise in diagnosing serious conditions like ALS and certain cancers. It has also been used in military settings to detect explosive devices. The goal is to make this advanced technology more affordable and accessible to the general public. Holmes, who has a young family, has not let her prison sentence dampen her ambitions. She has been working on new patents and plans to return to the biotech industry upon her release. Her conviction also includes a decade-long ban from serving as an officer or director of any public company, but this does not prevent her from advising private ventures like Haemanthus. The future of Haemanthus is uncertain, but its potential is clear. The company hopes to develop consumer-friendly products that can conduct medical tests using small samples of biological materials, such as sweat, urine, or saliva. This could make advanced medical diagnostics more accessible and convenient for everyone. The journey of Haemanthus is a complex one, intertwined with the controversial legacy of Theranos. While the new venture seeks to innovate, it also raises questions about the ethics and transparency of its founders. As Haemanthus continues to grow, it will be crucial for the company to learn from the past and build a future that prioritizes honesty and integrity.

Actions